U.S. Markets open in 1 hr 13 mins

Co-Diagnostics, Inc. (CODX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.54+0.38 (+3.74%)
At close: 4:00PM EST

10.75 +0.21 (1.99%)
Before hours: 8:09AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.16
Open10.40
Bid10.40 x 900
Ask10.90 x 800
Day's Range10.36 - 11.18
52 Week Range1.10 - 30.99
Volume2,086,143
Avg. Volume1,946,133
Market Cap297.957M
Beta (5Y Monthly)-1.77
PE Ratio (TTM)9.39
EPS (TTM)1.12
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.00
  • These Were the 5 Best Diagnostics Stocks of 2020
    Motley Fool

    These Were the 5 Best Diagnostics Stocks of 2020

    It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. Co-Diagnostics (NASDAQ: CODX), Aspira Women's Health (NASDAQ: AWH), Fulgent Genetics (NASDAQ: FLGT), GenMark Diagnostics (NASDAQ: GNMK), and Natera (NASDAQ: NTRA) were the five best-performing diagnostics companies last year among those with a market cap above $200 million.

  • Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference
    PR Newswire

    Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

    Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14.

  • Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
    PR Newswire

    Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

    Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is anticipated to be the highest in the Company's history and to surpass analyst estimates.